Sobi and Sanofi present positive efanesoctocog alfa data in hemophilia A

Stockholm-based biotech Swedish Orphan Biovitrum (STO: SOBI) and French drugmaker Sanofi (Euronext: SAN) have presented positive results from the XTEND-1 Phase III study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001).

The companies are evaluating the safety, efficacy and pharmacokinetics of the investigational factor VIII replacement therapy, in previously-treated adults and adolescents of at least 12 years with severe hemophilia A. They presented the data at the 30th International Society on Thrombosis and Hemostasis (ISTH) Congress.

"These unprecedented results may offer people with hemophilia A the possibility to redefine their treatment expectations"XTEND-1 met the primary efficacy endpoint, with once-weekly efanesoctocog alfa prophylaxis providing clinically meaningful bleed protection for people with severe hemophilia A.